Pozen drops one migraine drug, to pursue another
Posted on: Friday, 5 August 2005, 09:48 CDT
WASHINGTON (Reuters) - Pozen Inc. said on Friday it would no longer pursue U.S. approval of its experimental migraine drug MT 100, one day after a U.S. advisory panel said another clinical trial was needed.
Regulators had rejected the drug in May 2004 over concerns about the risk of users developing unusual tongue and mouth movements. MT 100 aimed to help migraine patients who do not have nausea.
Instead, the North Carolina-based drugmaker said it will continue pursuing its other headache medicine called Trexima, which it licensed to GlaxoSmithKline Plc for U.S. commercialization.
An ingredient in MT 100 -- metoclopramide -- has been associated with a potentially permanent, disabling movement disorder called tardive dyskinesia. The company has said Trexima does not carry that risk.
"Trexima has already demonstrated greater efficacy without the metoclopramide risk associated with MT 100," said John Plachetka, the company's chairman, president and chief executive.
Plachetka said the firm expected to file an application for approval of Trexima "shortly."
Pozen's shares were up 50 cents, or 6.27 percent, at $8.47 in morning trade on Nasdaq.
Source: REUTERS
Related Articles
- Chartis RiskTech100(TM) Report Reveals Major Gaps in Financial Institutions' Risk Management Strategies, and Increases in 2010 Technology Expenditure
- SANpulse Helps Leading Global Financial Conglomerate Undertake Massive SAN Migration and Delivers Record Performance
- Dollar Thrifty Automotive Group Reports Results, Ends 2008 With $230 Million in Unrestricted Cash
- Disclosure Insight Offers In-Depth Investment Research Reports on Ford and GM
- Minnesota IVF Practice Offers New 100% Risk Refund
- Palisade Systems Data Leak Device Finding Up to 100 Policy Violations During Initial Risk Assessments for Organizations Over Two Hour Period
- Kenya Risks Losing 100 Million Dollars Grant From Global Fund
- Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force
- An Earlier Read on Down Syndrome; A New Non-Invasive Test Uses Sonograms and Blood Analysis
- Prevention of Necrotising Enterocolitis: Year 2004 and Beyond
 |
 |
User Comments (0)
RSS Feeds